Moderna says company's COVID vaccine is 94.5 percent effective

Moderna's COVID-19 Vaccine Found 94.5% Effective | IE

U.S. biotech company Moderna on Monday announced a potential Covid-19 vaccine, which has been shown to be 94.5 per cent effective at protecting people from coronavirus, according to interim results from late-stage clinical trials. During study, 95 people were tested COVID-19 positive and only 5 of them belonged to the vaccinated group.

The current results were based on 95 cases, of which 90 cases of COVID-19 were observed in the group that received the placebo compared to five cases observed in the group that was administered the candidate, called mRNA-1273.

The study, which is jointly funded by the United Kingdom government, is the third of its kind to enter clinical trials in the United Kingdom, together with the vaccine candidates being developed by U.S. biotech company Novavax and University of Oxford/AstraZeneca.

"These results are very strong and suggest mRNA-based technologies can deliver so far for COVID-19 protection", Yee wrote this morning in a research note.

The COVE study enrolled over 30,000 participants in the USA and is still ongoing. "This includes more than 6,000 participants who identify as Hispanic or LatinX, and more than 3,000 participants who identify as Black or African American".

Another significant difference between the two leading vaccines: Moderna says its vaccine remains stable at 36 to 46 degrees Fahrenheit (2 to 8 degrees Celsius), and can be stored for six months at minus 4 degrees F (minus 20 degrees C), versus minus 94 degrees F (minus 70 degrees C) for BNT162b2. As mentioned, it's worth pointing out that this is just a first interim report, but it is data that comes from the safety board overseeing the trial appointed by the National Institutes of Health, which is an independent body not affiliated with Moderna, so it's a reliable result that provides hope for continued and final analysis.

This announcement follows that by USA giant Pfizer and Germany's BioNTech last week that their vaccine was found to be more than 90 per cent effective. Finding an effective vaccine with a good safety profile is a top priority in helping to protect us all more quickly against COVID-19.

"We look forward to the next milestones of submitting for an EUA in the USA, and regulatory filings in countries around the world, while we continue to collect data on the safety and efficacy of the vaccine in the COVE study", said Stéphane Bancel, Moderna's chief executive.

Moderna also said mRNA-1273 met a secondary endpoint analyzing severe cases of COVID-19, and including 11 severe cases as defined in the study protocol.

There were 11 people who fell severely ill, all of whom were in the placebo group.

After the first dose, about three percent of people had injection site pain classed as severe. The majority of adverse events were mild or moderate in severity.

Related:

Comments


Other news